YIDU TECH (02158) shares are soaring in intraday trading, with the stock price surging 5.57% to HK$6.06. The company's stock has seen active trading, with a turnover reaching HK$74.9734 million as of the latest update.

The significant uptick in YIDU TECH's stock price comes on the heels of a major announcement. The company revealed that its affiliated entity, Tianjin Happy Life Technology Co., Ltd., has successfully won the bid for a crucial clinical research project. The project involves Phase III clinical research for Shandong Yandu Biotechnology Co., Ltd.'s recombinant human nerve growth factor (SMR001) eye drop. The total value of this project is approximately RMB 55.82 million, marking a substantial business opportunity for YIDU TECH.

YIDU TECH, known as China's AI medical transformation driver, has positioned itself at the forefront of healthcare innovation. The company has developed a "data-algorithm-scenario" flywheel closed loop based on its proprietary core algorithm engine, YiduCore. This technology enables high-efficiency innovation and low-cost scaled application of AI technology, driving intelligent decision-making across the entire "medical-pharmaceutical-insurance-patient" ecosystem. The recent project win further solidifies YIDU TECH's role in advancing medical research and development in China's healthcare sector.